PG&E Interest Paid increased by 32.1% to $774.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.5%, from $707.00M to $774.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 17.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $152.00M | $527.00M | $175.00M | $519.00M | $184.00M | $592.00M | $312.00M | $598.00M | $470.00M | $693.00M | $525.00M | $712.00M | $487.00M | $712.00M | $510.00M | $707.00M | $575.00M | $797.00M | $586.00M | $774.00M |
| QoQ Change | — | +246.7% | -66.8% | +196.6% | -64.5% | +221.7% | -47.3% | +91.7% | -21.4% | +47.4% | -24.2% | +35.6% | -31.6% | +46.2% | -28.4% | +38.6% | -18.7% | +38.6% | -26.5% | +32.1% |
| YoY Change | — | — | — | — | +21.1% | +12.3% | +78.3% | +15.2% | +155.4% | +17.1% | +68.3% | +19.1% | +3.6% | +2.7% | -2.9% | -0.7% | +18.1% | +11.9% | +14.9% | +9.5% |